Reuters reports the FDA has shelved the Commissioner’s National Priority Voucher program, while another update highlights the tight Senate committee timeline around Heidi Overton’s nomination to lead the agency. Separately, a STAT piece warns that staffing shortages and leadership churn are still disrupting review consistency. The combination of policy shifts and operational constraints raises near-term uncertainty around review throughput and predictability for sponsors—particularly in areas dependent on timely regulatory feedback. Together, the reporting points to a regulator facing both headline-level program changes and day-to-day capacity strain.